Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2004

View Archived Issues

Synthetic flavonol reduces infarct size and myocardial injury in sheep

Prostaglandin E2 receptor agonist accelerates bone repair in rats

Chloride channel inhibitor prevents bone resorption in ovariectomized rats

Protective effects of vardenafil in the ischemic heart

Enrollment begins in phase II trial of MC-4232

Vicuron reports phase III results for dalbavancin in SSTIs

Sanctura distribution under way

BLA submission for Adacel vaccine

Adderall XR receives FDA approval for use in adults

A.P. Pharma reports initial data for APF-112 and APF-530

Dexanabinol receives orphan drug status

AV-201 cleared to enter phase I/II trial for Parkinson's disease

Spectrum acquires North American, Indian rights to D-631153

Enhance Biotech and Ardent Pharmaceuticals in definitive merger agreement

Topamax approved for migraine prophylaxis

New bradykinin antagonists emerges from Elan R&D

Mexican launch for Sucanon planned

Wyeth and Cambridge Antibody Technology claim new anti-PD-1 antibodies

Guilford plans major PCI trials for Aggrastat

Takeda scientists prepare and evaluate anti-urotensin II antibodies

NeuroSearch and TopoTarget collaborate on Endovion development

New monoamine reuptake inhibitors and their use in pain, emesis and other disorders

BMS researchers design novel serotonin receptor modulators for use as antiobesity agents

Novel factor Xa inhibitors in early development at Boehringer Ingelheim

New PPAR modulators prepared and evaluated by AstraZeneca team

Melanocortin receptor antagonist promising for treatment of obesity and affective disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...